Ialuril 50ml Prefill
Device50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
Other names: HA-CS
NCT Number: NCT05652374
The GT RACING is a study comparing the efficacy of HA-CS bladder installations with prophylactic antibiotics in the prevention of recurrent urinary tract infections (rUTI).
Interested in participating?
Request Info18 year and older
Female
Interventional
Phase 4
Radboudumc, Nijmegen, Gelderland, Netherlands
The main objective of the study is to compare efficacy between hyaluronic acid - chondroitin sulphate (HA-CS) treatment and gold standard treatment (AB prophylaxis). Study is set-up as non-inferiority, parallel group cross-over RCT, with a 1:1 randomization.
Study population: Female (>18rs) with at least 3 symptomatic urinary tract infections (UTI's) in the previous year with no adequate curable therapeutic options.
Intervention: 50ml of sterile Ialuril (HA 1.6% CS 2%) weekly for 6 weeks, followed by monthly maintenance therapy for 6 months.
Control : oral nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily will be given.
All patients recieve both treatments (ialuril and nitrofurantoin) consecutively, for 6 months each. The order of the therapies is determined by randomisation. Between therapies there is a 4 weeks 'wash-out' period. A total of 100 patients will be included.
During the study patients will fill-out questionnaires regarding symptoms, quality of life and use of healthcare. Furthermore urine will be collected at set timepoints.
Main study parameters/endpoints: The main study parameter is the number of UTI per patient-year. Secondary parameters are time to rUTI (wks.), outcome on the global responce assessment (GRA) scale, pattern of antibiotic resistance, outcome on the patient reported outcome questionnaire, cost effectiveness and Quality-of-life.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months
Other names: HA-CS
nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)
Time frame: 13 months
Number of urinary tract infections per patient-year
Time frame: 13 months
Time to first urinary tract infection
Time frame: 7 weeks, 3 months, 6 months after start of each therapy
Changes on Global Assessment of Improvement, Likert scale: -3 (worst) to +3(best)
Time frame: Baseline, 6 months after start of each therapy
Difference in acquired AB resistance (increase in resistance to different antibiotic treatments) between both patients groups
Time frame: Baseline, 6 months after start of each therapy
Difference in cost-effectiveness between the 2 therapies. This is assessed with the 'medical consumption questionnaire'
Time frame: Baseline, 6 months after start of each therapy
Difference in cost-effectiveness between the 2 therapies. This is assessed with the 'productivity cost questionnaire'
Time frame: baseline, 7 weeks, 3 months, 6 months after start of each therapy
Differences in therapy specific patient reported outcomes between both patient groups (measured in Therapy Specific Patient Reported Outcome (PRO) Questionnaire on Symptom & Bother rUTI & GAG therapy)
Time frame: baseline, 7 weeks, 3 months, 6 months after start of each therapy
Is there a difference in the Quality-of-life between the 2 therapies during follow-up using ED-5D 5L questionnaire
Contact information is provided by the study sponsor or research team.
Cléo Baars, MD
CONTACT
Dick Janssen, MD, PhD
CONTACT
Radboud University Medical Center
Other
Acronym: GT RACING
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04807894
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Brooklyn, New York, United States
View Trial DetailsNCT06940622
Cystitis, Cystitis Chronic
Dallas, Texas, United States
View Trial DetailsNCT06050148
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Helsinki, Finland
View Trial DetailsNCT05553652
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Hvidovre, Copenhagen, Denmark
View Trial Details